Prosecution Insights
Last updated: April 19, 2026

Biocryst Pharmaceuticals Inc.

2 pending office actions

Portfolio Summary

2
Total Pending OAs
1
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17767798 ORAL COMPLEMENT FACTOR D INHIBITORS SZNAIDMAN, MARCOS L 1628 Non-Final OA Apr 08, 2022
17630692 DOSING REGIMENS FOR ORAL COMPLEMENT FACTOR D INHIBITORS SIMMONS, CHRIS E 1622 Final Rejection Jan 27, 2022

Managing Biocryst Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month